Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CEO Samuel Kintz sold 526 shares of Enliven Therapeutics stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $27.54, for a total value of $14,486.04. Following the completion of the transaction, the chief executive officer now directly owns 1,048,729 shares in the company, valued at approximately $28,881,996.66. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Samuel Kintz also recently made the following trade(s):
- On Monday, August 26th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.89, for a total transaction of $274,680.00.
- On Wednesday, July 31st, Samuel Kintz sold 2,270 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.56, for a total transaction of $62,561.20.
- On Thursday, July 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.92, for a total transaction of $299,040.00.
Enliven Therapeutics Price Performance
Shares of NASDAQ ELVN opened at $27.53 on Friday. The company has a 50-day moving average price of $23.21 and a 200-day moving average price of $21.97. The stock has a market capitalization of $1.29 billion, a P/E ratio of -14.26 and a beta of 1.09. Enliven Therapeutics, Inc. has a 1 year low of $9.80 and a 1 year high of $27.67.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC lifted its stake in Enliven Therapeutics by 74.8% during the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after acquiring an additional 305,397 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Enliven Therapeutics by 49.2% during the second quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock valued at $2,667,000 after purchasing an additional 37,632 shares in the last quarter. First Turn Management LLC bought a new stake in Enliven Therapeutics in the 2nd quarter worth about $9,657,000. American Century Companies Inc. increased its stake in Enliven Therapeutics by 44.7% in the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock valued at $646,000 after buying an additional 8,540 shares during the last quarter. Finally, Nicholas Investment Partners LP bought a new position in shares of Enliven Therapeutics during the 2nd quarter worth approximately $1,310,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.
Analysts Set New Price Targets
Several research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a research report on Tuesday. Baird R W upgraded Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Finally, Robert W. Baird began coverage on shares of Enliven Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price objective for the company.
Get Our Latest Analysis on ELVN
Enliven Therapeutics Company Profile
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Articles
- Five stocks we like better than Enliven Therapeutics
- How to Use the MarketBeat Stock Screener
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- Compound Interest and Why It Matters When Investing
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Stock Splits, Do They Really Impact Investors?
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.